MAY 1 7 2004

\ <b>\</b>		Sheet 1 of 1 .		
PADEMARK SE	U.S. Department of Commerce Patent and Trademark Office		SERIAL NO. 09/905,243	
•	CLOSURE STATEMENT PLICANT	APPLICANT Taylor	•	
(Use several sheets if necessary)		FILING DATE Herewith	GROUP 1642	

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
-		FORE	IGN PATENT DOCUMENTS	•		
	Document Number	Date	Country	Class	Subclass	<u>Translation</u> Yes I No

Document Number	Date	Country	Class	Subclass	<u>Trans</u> Yes	lation No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Greenspan, NS, Bona, CA. Idiotypes:structures and immunogenicity. FASEB J. (1993) CA Mar;7(5):436-44. Abstract. Kuus-Reichel, et al. Will Immunogenicity Limit the Use, Efficacy, and Future Development of CB Therapeutic Monoclonal Antibodies? Clinical and Diagnostic Laboratory Immunology. July 1994, 1(4):365-372. DATE CONSIDERED **EXAMINER** 

•EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant.